title: Inhibition of diabetic bladder smooth muscle cell proliferation by endothelin receptor antagonists.
abstract: Urinary bladder hypertrophy and hyperplasia are well recognised in diabetic cystopathy. The urinary bladder is known to synthesise endothelin-1 (ET-1), a potent vasoconstrictor peptide with mitogenic properties. Using diabetic New Zealand White (NZW) rabbits, we investigated the potential role of ET receptor subtypes (ETA and ET(B)) on the proliferation of bladder smooth muscle cells (SMC). Diabetes mellitus was induced in adult male NZW rabbits. After 6 months, control (n = 6) and diabetic (n = 6) bladders were removed and SMC from the dome and bladder neck were grown using standard explant methodology. At passage two, the cells were made quiescent and then further incubated in foetal calf serum (FCS), control age-matched rabbit serum (CRS) or diabetic rabbit serum (DRS) in the presence or absence of ET(A)-antagonist (BQ123) or ET(B)-antagonist (BQ788). SMC proliferation was then measured with 5-bromo-2'deoxy-uracil 24 h later and by cell counting (using a haemocytometer) at 48 h. Neither BQ123 nor BQ788 influenced detrusor or bladder neck SMC proliferation in FCS or CRS. However, in the presence of DRS, BQ123 and BQ788 significantly inhibited diabetic detrusor and bladder neck SMC proliferation at 30 and 100 nmol/l (P < 0.03 and P < 0.01, respectively). Cell counts were also significantly reduced from the diabetic detrusor and bladder neck (P < 0.01 and P < 0.03 with BQ123 and BQ788, respectively). These results suggest that ET may play a pathophysiological role in the bladder SMC hyperplasia associated with diabetes mellitus.
authors.affiliation: Department of Urology, Royal Free Hospital, London, UK.
authors.forename: F H
authors.initials: FH
authors.lastname: Mumtaz
authors.forename: N
authors.initials: N
authors.lastname: Shukla
authors.forename: M E
authors.initials: ME
authors.lastname: Sullivan
authors.forename: C S
authors.initials: CS
authors.lastname: Thompson
authors.forename: M A
authors.initials: MA
authors.lastname: Khan
authors.forename: R J
authors.initials: RJ
authors.lastname: Morgan
authors.forename: G
authors.initials: G
authors.lastname: Stansby
authors.forename: D P
authors.initials: DP
authors.lastname: Mikhailidis
mesh_terms: D000818:Animals; D001973:Bromodeoxyuridine / Q000378:metabolism; D002452:Cell Count; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000473:pathology*; D065128:Endothelin Receptor Antagonists; D008297:Male; D009130:Muscle, Smooth / Q000378:metabolism / Q000473:pathology*; D009842:Oligopeptides / Q000494:pharmacology*; D010456:Peptides, Cyclic / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D011817:Rabbits; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D012016:Reference Values; D001743:Urinary Bladder / Q000378:metabolism / Q000473:pathology*
chemical_list: D065128:Endothelin Receptor Antagonists; D009842:Oligopeptides; D010456:Peptides, Cyclic; D010880:Piperidines; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; C086539:BQ 788; D001973:Bromodeoxyuridine; C072247:cyclo(Trp-Asp-Pro-Val-Leu)